Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of GDC-0853 in moderate to severe rheumatoid arthritis
2016-000498-19Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fenebrutinib in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoint: Long-term safety of GDC-0853. Started Aug 2016; status: completed.
02
Drugs
fenebrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-000498-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000498-19.